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Objectives: To compare the immunogenicity, safety, and interchangeability of two pediatric
hepatitis A vaccines, Avaxim 80U-Pediatric1 and Havrix 7201, in Chilean children.
Methods: In this randomized trial, 332 hepatitis A virus (HAV) seronegative children from 1 to 15
years of age received two doses of Avaxim, two doses of Havrix, or Havrix followed by Avaxim, 6
months apart. Anti-HAV antibody titers were measured before and 14 days after the first dose of
vaccine, and before and 28 days after the second dose of vaccine. Immediate reactions were
monitored; reactogenicity was evaluated from parental reports.
Results: Seroconversion rates after the first vaccination were 99.4% and 100% for Avaxim and
Havrix, respectively. Anti-HAV geometric mean concentrations (GMCs) were 138 mIU/ml for
Havrix (95% confidence interval (CI): 120; 159) and 311 mIU/ml for Avaxim (95% CI: 274; 353).
GMCs increased to 4008 mIU/ml after two doses of Havrix, 8537 mIU/ml following two doses of
Avaxim, and 7144 mIU/ml in children who received Havrix with Avaxim as the second dose.
Following the first injection, 36% of subjects given Avaxim and 44% given Havrix reported local
reactions; 38% of subjects in the Avaxim group and 40% in the Havrix group reported systemic
reactions related to vaccination. Solicited reactions were less frequent after the second dose of
Avaxim or Havrix, occurring in 27% to 37% of subjects.
Conclusions: No significant difference in seroconversion rates was seen 14 days after a single dose
of vaccine. A two-dose schedule with either vaccine or with Havrix/Avaxim provided a strong
booster response. Both vaccines were well tolerated and can be recommended for routine
vaccination of Chilean children. Avaxim 80 may be used to complete a vaccine schedule begun
with Havrix 720.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.§ This study was presented in part at the 11th International Congress on Infectious Diseases, Cancun, Mexico, 4—7 March 2004 (Abstract
10.007).
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In young children, hepatitis A is usually asymptomatic or
mild, but it increases in severity with age, so that in subjects
older than 5 years the infection is often clinically signifi-
cant.1,2 The epidemiological patterns of hepatitis A virus
(HAV) infection correlate with local socioeconomic condi-
tions, and since the most common mode of HAV transmission
is by the fecal—oral route, improvements in public health
lead to reduced HAV circulation.3,4 As sanitation improves,
decreased circulation of the virus results in groups of older
children and adolescents within a population who have not
yet been exposed, and remain susceptible to HAV infection.
Hepatitis A vaccination of toddlers can thus be a desirable
public health measure in countries where hepatitis endemi-
city is decreasing to intermediate or low levels.
The benefits obtained by universal vaccination of young
children have been confirmed in a growing list of countries.
Following the institution of universal vaccination of toddlers
at 18 and 24 months of age, the overall incidence of hepatitis
in Israel decreased from a mean of approximately 50 cases
per 100 000 per year from 1993 through 1998 to <2.5 cases
per 100 000 in 2002 and 2003.5 A similar program conducted
from 1995 to 2000 in California, USA, in children between 2
and 17 years of age, resulted in a decrease in HAVannual case
incidence from 57 to 1.9 per 100 000.6 Argentina began
universal vaccination of toddlers in 2005 following an
increase of 23% in the previous year in the number of
reported cases of hepatitis A, an overall annual incidence
of 171 per 100 000 compared to 139 per 100 000 during the
previous year.7
Recent epidemiological studies show that there has been a
shift from high to intermediate endemicity of HAV infection
throughout much of Latin America. Community seropreva-
lence studies show that as of the year 2000, only 11—12% of
Chilean children between 1 and 5 years of age had been
exposed to HAV, 25—30% at age 6—10 years, and it was only in
a cohort of 20—24 year-olds that the seroprevalence rate
reached approximately 70%.8—10 It is clear, however, that
these age-related changes in seroprevalence have not
occurred throughout the population, but are associated with
communities having a relatively high socioeconomic level.10
The Chilean data show that the decrease in overall HAV
seropositivity has not been associated with a smooth
decrease in incidence of clinical disease, but rather with
upward displacements in incidence or epidemic cycles, such
as occurred in 1994—1995 and the years 2002 and 2003.11,12
Epidemiologic data from Chile also indicate that the propor-
tion of hepatitis A cases in children younger than 5 years of
age has decreased from about 30% of the total in 1975 to 16%
in 2006. Over the same period of time, the proportion of
hepatitis A cases in adolescents and young adults between
the ages of 15 and 24 years has increased from approximately
5% to 18%. The shift in the average age of infection to one
when clinically significant illness is more likely has led to an
increasing tendency towards immunizing children at a young
age.7
Inactivated hepatitis A vaccines were first developed for
adult administration, to protect travelers to endemic areas.
However, extensive experience with inactivated hepatitis A
vaccines in prospective efficacy trials13,14 and intervention
studies during outbreaks15—17 have shown that vaccinationcould also protect children from infection. The potential for
routine vaccination of children to lower the overall incidence
of the disease has led to the development of pediatric
hepatitis A vaccine formulations containing reduced amounts
of hepatitis A viral antigen. The Avaxim pediatric vaccine
evaluated in this trial has been shown to be safe and immu-
nogenic in Israeli and Argentinean children aged from 1 to 15
years when given in two doses 6 months apart.18,19 A study in
Thai children confirmed the immunogenicity and safety of
the vaccine when the second dose was given at 6, 12, or 18
months after the first one.20 The safety profile of this vaccine
has been evaluated in more than 3000 subjects aged from 12
months to 15 years who received at least one dose of
pediatric inactivated hepatitis A vaccine.21
Comparative trials of the adult formulations of this vac-
cine, Avaxim 1601 (Sanofi Pasteur, Lyon, France) and Havrix
14401 (GlaxoSmithKline, Rixensart, Belgium), have demon-
strated that two doses given 6 months apart are strongly
immunogenic and well tolerated.22,23 Previous studies with
the adult formulations have also confirmed the interchange-
ability of these two vaccines.24
We conducted this study to evaluate the immunogenicity
and safety of the pediatric formulations of Avaxim and Havrix
(Avaxim 80U-Pediatric1 and Havrix 7201), and to evaluate




This was a monocenter, comparative trial in which healthy,
seronegative children were randomized to receive two doses
of hepatitis A vaccine 6 months apart. The trial was con-
ducted in accordance with the Edinburgh version of the
Declaration of Helsinki. The study was approved by the Ethics
Committee of the School of Medicine, Pontificia Universidad
Cato´lica de Chile. Parents or legal guardians of all partici-
pants gave written informed consent prior to study entry.
Eligible subjects were between 1 and 15 years of age and
anti-HAV seronegative. Subjects were excluded if they were
enrolled or scheduled to be enrolled in another clinical trial,
had an acute febrile illness (37.5 8C axillary or 38.4 8C
rectal temperature), had a known history of allergy to any
vaccine component, were unable to comply with the visit
schedule, had a chronic immunosuppressive disease or had
received immunosuppressive treatment within the month
prior to inclusion, had uncontrolled coagulopathy or a blood
disorder that contraindicates intramuscular injection, had
received blood and/or plasma transfusion or received any
immunoglobulins within the four months prior to inclusion,
had previously been vaccinated against hepatitis A, had a
previous history of hepatitis A, had hepatosplenomegaly on
the day of pre-selection/inclusion, or had a previous history
of treatment with growth hormone.
When enrolled, children were stratified to one of three
age groups of equal size (1—5, 6—10, or 11—15 years of age),
and then randomized to two equal groups (Figure 1). The first
group received two doses of Avaxim. The second group
received a first dose of Havrix, and the subjects were then
randomized to two subgroups of equal size for the second
injection, either Avaxim or a second dose of Havrix. Group
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Figure 1 Study design.allocations were determined using previously generated lists
of random numbers. As the two vaccines have different
packaging, the study could only be observer-blind.
Vaccines
Avaxim 80U is a formaldehyde-inactivated hepatitis A liquid
vaccine adsorbed onto aluminum hydroxide, containing 80
antigen units per 0.5 ml dose (aluminum hydroxide 0.15 mg,
2-phenoxyethanol 2.5 ml, formaldehyde 12.5 mg). Havrix 720
is a formaldehyde-inactivated hepatitis A liquid vaccine
adsorbedonto aluminumhydroxide, containing 720 ELISA units
per0.5 mldose(aluminumhydroxide0.25 mg,2-phenoxyetha-
nol 0.5%, formaldehyde 100 mg). The vaccines were adminis-
tered by intramuscular (IM) injection into the right deltoid.
Serological analysis
Blood samples for determination of anti-HAV antibody and
calculation of geometric mean concentrations (GMCs) were
obtained at enrollment, at 14  2 days after the first vacci-
nation, at 6 months (7, +21 days) just prior to second
vaccination, and at a month  4 days following the second
vaccination (Figure 1). Serum anti-HAV antibody concentra-
tions were determined using a commercially available
enzyme immunoassay (EIA) (ETI-AB-HAVK PLUS; DiaSorin,
Saluggia, Italy). Samples with values below the lowest limit
of quantification of 10 mIU/ml were assigned a value of
5 mIU/ml in order to calculate the GMC.
Reactogenicity and safety evaluation
The local and systemic reactogenicity of Avaxim and Havrix
were evaluated in all subjects following each injection.
Immediate reactions were monitored for 30 minutes. Soli-
cited local (pain, redness, or induration) and systemic (fever:
axillary temperature 37.5 8C, asthenia, headache, arthral-
gia, myalgia, gastrointestinal disorders) reactions occurring
within 3 days following any injection were recorded on diary
cards by parents or guardians. Unsolicited local and systemic
reactions and serious adverse events (SAEs) were recorded
throughout the study period. Adverse events were classified
according to their nature, severity, relationship to vaccina-
tion (for systemic reactions and SAEs), time of onset, and
duration.Statistical analysis
The primary study objective was comparison of the serocon-
version rates (increase in anti-HAV antibody concentration to
20 mIU/ml) for the two study vaccines, 2 weeks after the
first dose. The clinically relevant limit for between-group
differences in seroconversion rates was set at 10%. A 95%
confidence interval (CI) of the difference in rates between
Avaxim and Havrix entirely above 10% would then indicate
non-inferiority of the response to Avaxim. If the 95% CI of the
difference was entirely above zero, the Avaxim seroconver-
sion rate could be considered superior to Havrix. Seroconver-
sion rates and GMCs with 95% CIs were also calculated before
and after the second dose of vaccine in each study group.
Between-group comparisons of anti-HAV GMCs following each
of the two vaccine doses were descriptive only, based on the
95% CI. In addition, reverse cumulative distribution curves
(RCDCs) of anti-HAV antibodies were plotted for each study
group and each time point. Exploratory analyses were per-
formed in order to find a possible relationship between the
age of the subject and response to the vaccination using a
logistic regression for seroconversion rates with the treat-
ment group and age as covariates. Descriptive analysis of
reactogenicity included the numbers and percentages of
children who reported immediate or solicited reactions, with
95% CIs. All statistical analyses were performed by the
Biostatistics Platform of Sanofi Pasteur (Lyon, France) using
SAS software (SAS Institute, Cary, NC, USA).
Based on expected seroconversion rates of 94% for each
vaccine following the first dose, a type I error of 2.5% and a
power of 90%, a sample size of 120 subjects per group was
required for a non-inferiority test. The final sample size of
132 subjects was determined by assuming that 10% of sub-
jects would be excluded from the analysis, including those
lost to follow-up. The study protocol was amended to enroll
68 additional subjects because the batch number of vaccine
used was not indicated on the randomization list for 68
subjects who had been included in the trial.
Results
Subjects
A total of 332 seronegative children (anti-HAV concentration
<10 mIU/ml) were enrolled. Demographics were similar for
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Table 1 Characteristics of the study populationa
Group A Group B Subgroup B1 Subgroup B2 Total
Number of subjects (N) 164 166 84 82 330
Male 80 (49) 77 (46) 38 (45) 39 (48) 157 (48)
Female 84 (51) 89 (54) 46 (55) 43 (52) 173 (52)
Age 1—5 years 54 (33) 54 (32) 26 (31) 28 (34) 108 (33)
Age 6—10 years 58 (35) 59 (36) 31 (37) 28 (34) 117 (35)
Age 11—15 years 52 (32) 53 (32) 27 (32) 26 (32) 105 (32)
a Excludes one subject in group A and one in group B who received a first vaccination, but withdrew voluntarily before a post-vaccination
serum sample could be obtained at 14 days. Results are n (%).all study treatment groups (Table 1). A total of nine subjects
discontinued the study, five in group A and four in group B.
Three subjects withdrew voluntarily and one was lost to
follow-up. Two subjects were withdrawn by the sponsor
because the maximum time allowed between the first and
second dose had been exceeded. One subject was withdrawn
by the investigator because of hepatitis A infection. This was
not considered as a vaccine failure because symptoms
appeared 15 days after the first injection, consistent with
infection before vaccination. The subject recovered without
hospitalization. Another subject was withdrawn by the inves-
tigator because the person who signed the consent form was
not the parent or legal guardian of the child. One subject
received immunotherapy for glomerulonephritis and discon-
tinued the study because of receiving a prohibited treat-
ment. No patient withdrew because of a serious adverse
reaction.
Immunogenicity: first vaccine dose
The seroconversion rates in response to Avaxim and Havrix on
day 14 were 99.4% and 100%, respectively. The 95% CI of the
difference between the seroconversion rates for the two
vaccines was 4.3; 2.1. Of the 330 evaluable subjects on
day 14, one in the Avaxim group did not have an anti-HAV
antibody concentration 20 mIU/ml. This subject had ser-Figure 2 Anti-HAV (mIU/ml) 14 days following the first dose of
vaccine.oconverted by the time the second evaluation was done
before the second vaccine dose. The GMCs on day 14 were
311 mIU/ml (95% CI: 274; 353) in subjects receiving Avaxim
and 138 mIU/ml (95% CI: 120; 159) in those receiving Havrix,
and the anti-HAV concentrations are shown in Figure 2 in
RCDCs. GMCs for the study vaccines within each age group are
shown in Figure 3. A regression analysis with age cohorts and
vaccine groups as covariates showed a statistically significant
interaction between age and treatment group GMCs in
response to the first vaccine dose ( p = 0.04). The relationship
of age and GMCs was statistically significant in the Avaxim
group ( p < 0.0001), but this was not observed in the Havrix
group. GMCs decreased with increasing age of the subjects,
but still remained numerically higher than the GMCs in the
Havrix group.
Immunogenicity: second vaccine dose
GMCs in all groups decreased in the six-month interval before
administration of the second dose, but all subjects, except
one in the Havrix group, remained seroconverted (Table 2).
Post- to pre-second dose GMC ratios (Table 2) show that both
Avaxim and Havrix induced a marked booster-like response
within a month. The anti-HAVantibody GMCs were 8537 mIU/
ml (Avaxim/Avaxim), 7144 mIU/ml (Havrix/Avaxim), and
4008 mIU/ml (Havrix/Havrix) a month after the second dose
(Table 2). There were no non-responders to the second
vaccine dose. The overall responses to the second injection
in each treatment group are illustrated by the RCDCs in
Figure 4. Regression analysis showed no age effect on GMC
after the second dose in any group for either of the study
vaccines ( p = 0.6625).Figure 3 Geometric mean concentrations (mIU/ml) of anti-
HAV antibodies 14 days after the first dose of vaccine.
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Table 2 Anti-HAV antibody GMC, seroconversion rates (20 mIU/ml) pre- and post-second vaccination, and post-/pre-second
vaccination GMC ratios
Avaxim/Avaxim Havrix/Havrix Havrix/Avaxim
Pre- Post- Pre- Post- Pre- Post-
n 159 160 83 83 80 80
GMC (mIU/ml) 273 8537 117 4008 110 7144
95% CI 242; 309 7768; 9382 99.0; 138 3261; 4926 86.8; 138 5907; 8640
% (n) 100 (159) 100 (160) 100 (83) 100 (83) 98.8 (79) 100 (80)
(95% CI) 97.7; 100 97.7; 100 95.7; 100 95.7; 100 93.2; 100 95.5; 100
Post-/pre- Post-/pre- Post-/pre-
n 159 83 80
GMC ratio 31.1 34.3 65.2
(95% CI) 28.0; 34.6 28.9; 40.7 53.5; 79.4
HAV, hepatitis A virus; GMC, geometric mean concentration; CI, confidence interval.Safety: immediate reactions
Three children given Avaxim (2.3%) and eight subjects receiv-
ing Havrix (6%) had immediate reactions following the first
dose; all were mild and all resolved within 3 days, except in
one child with moderate pain and another with mild indura-
tion in the Havrix group, both lasting 4 days. Immediate
reactions were experienced by six subjects following a sec-
ond Avaxim dose (4.8%), four children after a second Havrix
dose (6%), and in two given Avaxim after a first dose of Havrix
(3.1%). Pain was the most commonly reported reaction: mild,
lasting 24 hours in five subjects receiving Avaxim, and severe,
lasting one to three days in two subjects given Havrix. Mild
redness lasting less than 2 days occurred in two patients given
Avaxim and 4 days in one patient receiving Havrix.
Safety: solicited local and systemic reactions
Overall, 36% (95% CI: 27.9; 45) of subjects given Avaxim and
44% (95% CI: 35.5; 52.9) of subjects who received Havrix
reported local reactions during the 3 days following the firstFigure 4 Anti-HAV concentrations (mIU/ml) at the time of
(Pre), and one month after (Post) the second dose of vaccine.dose of vaccine. Pain was the most frequent reaction,
reported by 31—38% of subjects, followed by induration
and redness, which occurred in 9—12% and 5—8% of children,
respectively (Table 3). Following the second dose, from 27%
(95% CI: 19.5; 35.6) to 37% (95% CI: 24.3; 48.9) of the children
experienced a solicited local reaction, and again pain was the
most frequently reported (Table 4). Most reactions were of
mild or moderate intensity.
Systemic reactions related to vaccination occurred in 38%
of subjects in the Avaxim group and 40% in the Havrix group
following the first injection. The occurrence of systemic reac-
tions after the second vaccination was slightly lower in both
study groups, ranging from 31% to 33%. Most reactions were of
mild to moderate intensity and resolved within 3 days. Head-
ache and asthenia were the most common reactions (Table 4).
Safety: unsolicited local and systemic reactions
Few unsolicited reactions occurred following injection of
either vaccine. Three local reactions occurred following the
first Avaxim injection (2%) and six occurred following Havrix
(4%). The unsolicited reactions included purpura, injection
site mass, pruritus, and hematoma. Only one unsolicited
systemic reaction occurred — severe somnolence following
the first injection of vaccine (Havrix), which resolved in 1 day.
Therewerenounsolicited local or systemic reactions following
an Avaxim for the second injection, but one subject had mild
injection site pruritus and another had mild ecchymoses after
receiving Havrix as a second injection. One subject experi-
enced severe somnolence lasting 1 day concomitant with
severe asthenia and mild headache following a Havrix as a
second dose. A total of 11 SAEs were reported, none were
related to vaccination. These included threeupper respiratory
disorders, six planned surgeries, a testicular cancer, and a
glomerulonephritis. Therewere no studywithdrawals because
of SAEs. The subject with glomerulonephritis, reported as an
SAE, discontinued the study because she received immuno-
suppressive therapy, a prohibited treatment.
Discussion
This randomized trial compared the immune response, safety,
and tolerability of two pediatric hepatitis A vaccines, Avaxim
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Table 3 Incidence of solicited local and systemic adverse
reactions within 3 days after the first injection
Avaxim Havrix
n % n %
Vaccinated 130 100 134 100
Any local reaction 47 36 59 44
Pain 40 31 51 38
Induration 12 9 16 12
Redness 7 5 10 8
Any systemic reaction 49 38 54 40
Fever 3 2 5 4
Asthenia 17 13 19 14
Headache 23 18 32 24
Arthralgia 6 4 12 9
Myalgia 9 7 13 10
Gastrointestinal disorders 13 10 14 1080U-Pediatric and Havrix 720. Both vaccines were highly
immunogenic, with all but one study subject in the Avaxim
group seroconverting within 14 days of receiving a single dose.
As shown by the 95% CI, there was no difference in the
seroconversion rates in response to the first dose of these
two vaccines. Overall however, GMCs were higher in response
to Avaxim: 311 mIU/ml versus 138 mIU/ml, and within each
age group the GMCs were higher in response to Avaxim. The
kinetics of antibody response after the first dose followed the
same pattern as seen in studies of the adult formulations of
these vaccines, with higher antibody concentrations observed
with Avaxim at week 2 than with Havrix.22,25 A previous study
with Avaxim had shown a trend for higher GMCs in response to
vaccination in younger, as compared with older, children.18 In
our study, the GMCs following vaccination with a first dose of
Avaxim were higher in the younger subjects (p < 0.0001), but
this was not the case for Havrix (p = 0.3699).
Anti-HAV GMCs decreased in the 6-month interval
between injections, but all subjects, except one who hadTable 4 Solicited local and systemic adverse events occur-







n % n % n %
Number vaccinated 126 100 67 100 64 100
Any local reaction 34 27 25 37 23 36
Pain 29 23 22 33 20 31
Redness 8 6 3 4 5 8
Induration 9 7 10 15 5 8
Any systemic reaction 41 33 21 31 21 33
Fever 6 5 4 6 5 8
Asthenia 24 19 7 10 9 14
Headache 15 12 10 15 13 20
Arthralgia 6 5 4 6 2 3
Myalgia 6 5 3 4 3 5
Gastrointestinal disorder 13 10 7 10 1 2received Havrix, remained seroconverted. The second dose
of both vaccines induced a marked response in all children.
The observed increases in GMC following the second dose
suggest that immunological priming with both vaccines had
been adequate. The responses in subjects given Avaxim/
Avaxim and Havrix/Avaxim indicate that Avaxim may be used
to complete a vaccination series begun with Havrix. The
increase in GMCs did not demonstrate an age-related effect
in any study group ( p = 0.6625) in response to the second
injection. The responses to the second dose of these pedia-
tric vaccines are consistent with previous trials that con-
firmed the interchangeability of the adult formulations of
these vaccines, using Avaxim to complete a series begun with
Havrix.22—24 Published models of antibody persistence with
both Avaxim and Havrix in adults show long-term rates of
decline for both vaccines. Projections extrapolating the
decreases in anti-HAV antibody concentrations indicate that
between 50% and 60% of vaccinees would still be seropro-
tected 10 years after vaccination, and that antibody persis-
tence could last up to 20 years.26,27 However, similar analyses
are not yet available for two doses of each vaccine in
pediatric subjects.
The high seroconversion rates seen here for both vaccines
make them suitable for universal childhood vaccination.
However, increased immune response in children younger
than 5 years of age, and high GMCs at 2 weeks following
administration of a single dose of vaccine, such as seen with
Avaxim, may be particularly useful for control of outbreaks.
Vaccination, when used during hepatitis A outbreaks, is
consistently followed by a rapid decline in incidence of
new cases, most likely related to reductions of secondary
transmission and sub-clinical cases that play a role in main-
taining the outbreak.28 Data from randomized trials are
limited, but in a study of household contacts of individuals
diagnosed with primary hepatitis A infection, vaccination was
approximately 80% effective for prevention of secondary
infection.29 The effectiveness may be correlated with the
rate at which antibody concentrations rise to protective
levels following vaccination, but confirmatory data from
clinical trials are lacking.
The overall reactogenicity was somewhat better than that
seen in trials of the adult formulations of these vaccines and
comparable to other studies that evaluated these pediatric
vaccines.14—19,27,30 The incidence of both solicited local and
systemic reactions was somewhat lower in all study groups
following the second dose than after the first dose. Immediate
reactions were seen in 3—6% of patients, and as in the other
studies, injection site pain was the most frequent reaction,
followed by redness. Only two reactions were severe, local
pain in children receiving Havrix. The local safety profile was
satisfactory in both groups, with approximately 8% fewer
patients reporting a reaction after receiving Avaxim. Pain
was the most frequently solicited local reaction after any
injection, and most reactions were of mild or moderate inten-
sity. No SAEs occurred that were related to vaccination.
Experience in Israel and in the Catalonian region of Spain
have demonstrated that universal childhood immunization
against HAV is feasible and sustainable, and results in a
remarkable reduction of HAV disease not only in children
but also in other age groups.5,31 The Advisory Committee on
Immunization Practices (ACIP) in the USA recently recom-
mended universal vaccination of children between the ages
276 K. Abarca et al.of 2 and 18, following confirmation that selective vaccination
of children in states with the highest incidence of hepatitis A
had reduced the incidence to lower levels than the overall
national incidence.32 A recent health—economic analysis
concluded that decreases in the incidence of hepatitis A
within all age groups following vaccination of Chilean chil-
dren would result in reductions in medical costs and lost
productivity that would quickly outweigh the costs of vacci-
nation.33
The availability of alternative vaccines is likely to facilitate
the implementation of a program of universal vaccination of
young children. The increasing need for hepatitis A vaccine
could easily mean that a single manufacturer could not satisfy
demand. Because of potential differences in availability, it is
important to show that a schedule begun with a vaccine from
onemanufacturer can be completed with one obtained from a
different provider. In many cases the hepatitis A vaccines
administered in one clinic or office practice will be different
from those available from others, or it may not be known
which product was administered previously. In addition,
healthcare systems may change from stocking vaccines from
one manufacturer to another. In such circumstances, the
physician often has no choice but to switch brands during
the series. Thus, for a number of reasons, it may not always be
feasible or practical to give children a single manufacturer’s
vaccine for both of the required vaccinations. Physicians faced
with the necessity of givingmixed sequences should know that
the mixed schedule would be well tolerated and protective.
The immunogenicity and safety results in this study support
the use of both vaccines for routine childhood vaccination in
Chile, and also show that a vaccination schedule started with
Havrix may be completed with Avaxim.
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